[
    [
        {
            "time": "",
            "original_text": "[增持评级]医药生物行业周报：在整体市场调整中建议积极关注医药板块的优质公司",
            "features": {
                "keywords": [
                    "医药",
                    "生物",
                    "市场调整",
                    "优质公司"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "[增持评级]医药生物行业周报：在整体市场调整中建议积极关注医药板块的优质公司",
                "Correlation": 8,
                "Sentiment": 7,
                "Importance": 6,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 4,
                "Market_Scope": 9,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "[领先大市-A评级]医药行业每周观点：继续关注Q1业绩超预期和业绩落地支撑盈利向上 以及白马股调整带来投资机会",
            "features": {
                "keywords": [
                    "医药",
                    "Q1业绩",
                    "白马股",
                    "投资机会"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "[领先大市-A评级]医药行业每周观点：继续关注Q1业绩超预期和业绩落地支撑盈利向上 以及白马股调整带来投资机会",
                "Correlation": 8,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 3,
                "Market_Scope": 9,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "医疗保健：建议积极关注医药板块 荐4股",
            "features": {
                "keywords": [
                    "医疗保健",
                    "医药板块",
                    "荐股"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "医疗保健：建议积极关注医药板块 荐4股",
                "Correlation": 7,
                "Sentiment": 7,
                "Importance": 6,
                "Impact": 5,
                "Duration": 4,
                "Entity_Density": 5,
                "Market_Scope": 8,
                "Time_Proximity": 5,
                "Headline_Structure": 6,
                "Source_Recency": 6
            }
        },
        {
            "time": "",
            "original_text": "[强于大市评级]医药生物行业研究周报：板块估值持续消化 抓住成长股机遇",
            "features": {
                "keywords": [
                    "医药",
                    "生物",
                    "估值",
                    "成长股"
                ],
                "sentiment_score": 0.75,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "[强于大市评级]医药生物行业研究周报：板块估值持续消化 抓住成长股机遇",
                "Correlation": 8,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 4,
                "Market_Scope": 9,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "[买入评级]泰格医药(300347)：公司内生增长强劲 将长期受益于创新药产业发展",
            "features": {
                "keywords": [
                    "泰格医药",
                    "内生增长",
                    "创新药"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "[买入评级]泰格医药(300347)：公司内生增长强劲 将长期受益于创新药产业发展",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "[推荐评级]泰格医药(300347)年报点评：仿创需求皆旺盛 CRO龙头进入发展快车道",
            "features": {
                "keywords": [
                    "泰格医药",
                    "年报",
                    "CRO",
                    "龙头"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "[推荐评级]泰格医药(300347)年报点评：仿创需求皆旺盛 CRO龙头进入发展快车道",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 9,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "original_text": "医药生物行业周报：短期调整不改长期看好 重点关注意年报及一季报",
            "features": {
                "keywords": [
                    "医药",
                    "生物",
                    "短期调整",
                    "年报",
                    "一季报"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "医药生物行业周报：短期调整不改长期看好 重点关注意年报及一季报",
                "Correlation": 7,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 3,
                "Market_Scope": 9,
                "Time_Proximity": 6,
                "Headline_Structure": 6,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "泰格医药:业绩如期高增长 持续受益于鼓励创新与一致性评价推进",
            "features": {
                "keywords": [
                    "泰格医药",
                    "业绩增长",
                    "创新",
                    "一致性评价"
                ],
                "sentiment_score": 0.9,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "泰格医药:业绩如期高增长 持续受益于鼓励创新与一致性评价推进",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 9,
                "Duration": 9,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 9,
                "Source_Recency": 9
            }
        }
    ]
]